Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9-Reference-Cited by-同舟云学术

Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9

Published:2024-08-12 Issue:16 Volume:67 Page:14125-14154
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Changwei¹,Wang Mi¹,Wang Yu¹,Rej Rohan Kalyan¹^ORCID,Aguilar Angelo¹,Xu Tianfeng¹^ORCID,Bai Longchuan¹,Tošović Jelena¹^ORCID,McEachern Donna¹,Li Qiuxia²,Sarkari Farzad²,Wen Bo²³,Sun Duxin²³^ORCID,Wang Shaomeng¹⁴⁵³^ORCID

Affiliation:

1. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States

3. Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States

4. Department of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States

5. Department of Medicinal Chemistry, College of Pharmacy,, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

National Cancer Institute

Oncopia Therapeutics Inc.

Proteovant Therapeutics Inc.

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00971

Reference63 articles.

1. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes

2. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma

3. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics

4. Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma

5. Cancer-Associated Gain-of-Function Mutations Activate a SWI/SNF-Family Regulatory Hub